Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2024 10:00 ET | Source: BioNTech SE

Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom

Erste Daten aus einer laufenden Phase-2-Studie zeigten eine 12-Monats-Gesamtüberlebensrate von 69 % und ein medianes Gesamtüberleben von 17,5 Monaten bei Patientinnen und Patienten mit vorbehandeltem,...
June 01, 2024 10:00 ET | Source: BioNTech SE

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic...
August 05, 2022 06:45 ET | Source: BioNTech SE

BioNTech und Genmab erweitern globale strategische Kollaboration zur Entwicklung und Vermarktung neuartiger Immuntherapiekandidaten

Ausweitung der Kollaboration zur Entwicklung monospezifischer Antikörperkandidaten gegen bösartige solide TumoreKollaboration nutzt Genmabs firmeneigene HexaBody®-Technologieplattform, um neuartige...
August 05, 2022 06:45 ET | Source: BioNTech SE

BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors Expanded collaboration leverages Genmab’s proprietary HexaBody® technology platform...
October 14, 2020 17:00 ET | Source: BioNTech SE

BioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs at SITC 35th Annual Meeting

Data updates from key oncology collaborations to be presentedPreliminary data from the first-in-human trial from intratumoral immunotherapy program BNT131 (SAR441000) in collaboration with Sanofi, to...
December 19, 2019 11:05 ET | Source: CureVac AG

Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics

Company Announcement Genmab and CureVac enter broad strategic partnership Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year...